• Ezequiel J Zaidel, Fernando S Wyss Quintana, Álvaro Sosa Liprandi, Iván Mendoza, Manlio F Márquez, Elaine Nuñez, Marcia Barbosa, and Adrián Baranchuk.
• Grupo de Trabajo COVID-19 de la Sociedad Interamericana de Cardiología. E-mail: ezezaidel@gmail.com.
• Medicina (B Aires). 2020 Jan 1; 80 (3): 271-274.

AbstractDue to the coronavirus disease 2019 (COVID-19) pandemic, a wide number of compounds are under scrutiny regarding their antiviral activity, one of them being hydroxychloroquine. Cardiac aspects of the use of chloroquine and hydroxychloroquine are reviewed in this manuscript. A non-systematic review of the medical literature was performed. Information about their safety and efficacy as antimalarials, antivirals, as well as in the long-term treatment of rheumatic diseases was collected. We found an anti-inflammatory effect with reduction of longterm cardiovascular events, a very infrequent heart disease due to a lysosomal effect of the drug, and at the hemodynamic level hypotension, tachycardia, and QT interval prolongation, exacerbated when combined with azithromycin. However, the rate of adverse cardiac events of hydroxychloroquine (and chloroquine) was low.

33 keywords...

hide…